Bone pain palliation with Strontium-89 in cancer patients with bone metastases

摘要

Strontium-89 is a pure β-emitting radioisotope, a chem- ical analogue of calcium, and it is therefore avidly con- centrated by areas of high osteoblastic activity. Selective uptake and prolonged retention at sites of increased bone mineral turnover provide precise bone lesions targeting. ~89Sr chloride (commercialised as Metastron) is typically administered in a signle 150 MBq parenter- al dose. Its radioactive emission poses very little radio- protection concerns. Overall, studies show pain relief in up to 80 /100 of patients, of which 10 to 40 /100 became effec- tively pain free.